- Email: [email protected]
Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients
abstracts
Annals of Oncology 1502P
First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Background: Pembrolizumab significantly improves progression-free survival (PFS) (median 10.3 months) and overall survival (OS) (median 30.0 months) in selected patients with previously untreated advanced non–small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) 50% and without EGFR/ALK aberrations. Data in real life conditions are missing. Methods: This was a cross-sectional, retrospective study of untreated advanced NSCLC patients with TPS 50% and without EGFR/ALK aberrations, from 9 French hospitals in Brittany area. The study included 115 patients and analysis focused on 108 patients. At index, the main characteristics of our cohort were: median age [range] 66.7 [37 to 87] years, 71 % male, 23.1 % performans status (P.S) 2, 88.8 % current or former smokers. 87.1 % had Stage IV at diagnosis and 9.2 % had untreated brain metastasis. 23.4% had mutations (KRAS, MET, BRAF and ROS 1). We used Kaplan-Meier analysis for PFS and described tolerability. Results: With a median follow-up of 7.1 months, median PFS was 10.1 months (95% confidence interval [CI], 8.8 to 11.4), (range, and 0.6 to 18.5 months). The objective response rate was 58,2% (complete response: 2.7 % and partial response: 55.5 %). Disease control rate was 72.1%. The estimated rate of OS at 6 months was 86.6 %. Treatment-related adverse events of grade 3 (AE) occurred in 7.4% of patients. There was no grade 4 or 5 AE and mean time between first administration of pembrolizumab and clinico-biological AE was 13.9 (6 9.7) weeks. Our data are immature to appreciate OS. Conclusions: In a real life cohort of patients (PS 2, untreated brain metastasis), with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab demonstrates similar PFS with KEYNOTE-024 phase III trial. Legal entity responsible for the study: Renaud Descourt. Funding: Association Bretonne de Cance´rologie Thoracique (ABCT). Disclosure: R. Corre: Travel / Accommodation / Expenses, Officer / Board of Directors: bms. G. Robinet: Advisory / Consultancy: MSD; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): BMS; Research grant / Funding (institution): Roche. R. Descourt: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: takeda; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Travel / Accommodation / Expenses: Pfizer. All other authors have declared no conflicts of interest. Linguistic correction
1503P
Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients
T. Sugano, M. Seike, Y. Saito, N. Takano, K. Hisakane, S. Takahashi, T. Tanaka, T. Kashiwada, S. Nakamichi, S. Takeuchi, A. Miyanaga, Y. Minegishi, R. Noro, K. Kubota, A. Gemma Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan Background: Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD associates with treatment efficacy and to research the characteristics of ILD in advanced non-small-cell lung cancer (NSCLC). Methods: Between December 2015 and November 2018, 132 advanced NSCLC patients were treated with nivolumab, pembrolizumab or atezolizumab. The patients were categorized into two groups (irAEs group or non-irAEs group). Subsequently, we extracted patients based on the incidence of ILD (ILD group). Treatment efficacy and characteristics of ILD were evaluated in each group. Results: The 39 (30%) patients developed irAEs. ILD was observed in 16 (12%) patients. Patients with ILD had significantly higher objective response rate (ORR) compared with irAEs-non-ILD patients and non-irAEs patients (63%, 43% and 22%, respectively). Median progression-free survival (mPFS) was 15.9 months in the ILD patients, 5.4 months in the irAEs-non-ILD patients and 3.3 months in the non-irAEs patients (Log rank, P ¼ 0.035). Pre-existing interstitial pneumonia (IP) was an independent risk factor of ILD-induced ICIs (odds ratios 15.1; 95% CI: 2.23-102, P ¼ 0.005).
Volume 30 | Supplement 5 | October 2019
1504P
Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Y. Kawashima1, O. Yamaguchi2, T. Kozuki3, N. Furuya4, F. Kurimoto5, T. Okuno6, T. Yamada7, K. Komiyama8, R. Ko9, Y. Nagai10, N. Ishikawa11, T. Harada12, K. Watanabe13, M. Seike14, K. Yoshimura15, K. Kobayashi2, H. Kagamu2 1 Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan, 2 Department of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama, Japan, 3Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, 4Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 5Thoracic Oncology, Saitama Cancer Center, Saitama, Japan, 6Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan, 7Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan, 8Department of Respiratory Medicine, Saitama Medical University Hospital, Saitama, Japan, 9Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan, 10Department of Pulmonary Medicine, Jichi Medical University, Tochigi, Japan, 11Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan, 12Center for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan, 13Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan, 14Division of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, 15 Department of Biostatistics, Innovative Clinical Research Center, Kanazawa University Hospital, Kanazawa, Japan Background: Although anti-PD-1 antibodies are the most promising agents in advanced non-small cell lung cancer (NSCLC), no definitive biomarkers of efficacy exist. We developed a novel assay for peripheral blood mononuclear cell (PBMC) biomarker using the prediction formula consisting of CD62L-downregulated (CD62Llow) CD4þT cells and CD25þFoxp3þCD4þT cells. This study aimed to validate it. Methods: This prospective multicenter phase II study included patients with treated advanced or metastatic NSCLC. After registration and PBMC biomarker analysis, they were classified into responder (RT) or non-responder (NRT) type. Nivolumab was administered every two weeks. The primary endpoint was disease control rate (DCR) at nine weeks after nivolumab treatment in RT patients. Desired and threshold DCR were set at 80% and 60%, respectively. Secondary endpoints were objective response rate (ORR), time to treatment failure, progression-free survival (PFS), overall survival, safety and tolerability, comparison with NRT patients, and PBMC biomarker quality improvement. Results: Of the 96 enrolled patients, 95 were eligible for PBMC analysis: 3 were unanalyzable, and 92 were analyzed; however, 40 had a minimal number of live cells. We excluded 19 patients who did not receive nivolumab in NRT and 1 with indeterminable treatment effect at nine weeks, and 72 patients comprised the per protocol set (PPS), of which 43 were RT and 29 NRT. The DCR and ORR in RT patients were 65.1% (95% confidence interval [CI], 50.9-79.4%) and 14.0% (95% CI, 3.6-24.3%), respectively. The PFS in RT patients was 113 days (95% CI, 65-158). As a subset analysis, we examined 45 patients (25 RT and 20 NRT) excluding those with 50% dead cell ratio in lymphocyte culture. The DCR was 80.0% (95%CI, 64.3-95.7) in RT and 50.0% (95% CI, 28.1-71.9) in NRT (chi-square test, p ¼ 0.034). Conclusions: In alive PBMC analysis, DCR was better in the RT than in the NRT patients. This PBMC biomarker using the ratio of CD62LlowCD4þT cells to CD25þFoxp3þCD4þT cells might be promising for predicting nivolumab efficacy. Clinical trial identification: UMIN ID: UMIN000028468. Legal entity responsible for the study: North East Japan Study Group (NEJSG). Funding: Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K. Disclosure: O. Yamaguchi: Research grant / Funding (institution): Nihon Medi-Physics Co., Ltd.; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Ono Pharmaceutical; Speaker Bureau / Expert testimony: Bristol-Myers Squibb. T. Kozuki: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Nippon Beohringer Ingelheim Co.; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical Co.; Honoraria (self): Kyowa-Hakko Kirin; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan; Research grant / Funding (institution): Merck Biopharm; Honoraria (self): MSD; Honoraria (self): Ono Pharmaceutical Co.; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical Co. N. Furuya: Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Lilly; Honoraria (self): Chugai Pharma ; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Ono Pharmaceutical. T. Yamada: Research grant / Funding (self): Ono Pharmaceutical Co., Ltd.; Research grant / Funding (self): Boehringer Ingelheim Japan Inc.; Research grant / Funding (self): Takeda Pharmaceutical Co. Ltd.; Research grant / Funding (self): Chugai Pharmaceutical Co., Ltd. R. Ko: Honoraria (self): Ono Pharmaceutical Co., Ltd. T. Harada: Honoraria (institution): Boehringer Ingelheim; Honoraria (institution): Hisamitsu Pharmaceutical Co., Inc; Honoraria (institution): GlaxoSmithKleine K.K. M. Seike: Honoraria (self), Research grant /
doi:10.1093/annonc/mdz260 | v617
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz260.025/5577677 by guest on 26 October 2019
K. Amrane1, M. Geier1, R. Corre2, G. Le´veiller3, G. Florence4, R. Lamy5, J.L. Bizec6, E. Goarant7, G. Robinet8, S. Ulrike9, G. Quere1, C. Bernier10, R. Descourt1 1 Department of Oncology, C.H.U. Brest - Hoˆpital Morvan, Brest, France, 2Department of Pulmonary Diseases, CHU de Pontchaillou, Rennes, France, 3Department of Pulmonary Diseases, CH Yves le Foll, Saint Brieuc, France, 4Department of Pulmonary Diseases, CH Pays de Morlaix, Morlaix, France, 5Department of Oncology, CH Bretagne Sud, Lorient, France, 6Department of Pulmonary Diseases, CH Bretagne-Atlantique, Vannes, France, 7 Department of Pulmonary Diseases, Hospital of Saint-Malo, Saint Malo, France, 8 Department of Oncology, C.H.U. Brest - Hoˆpital Morvan, Brest, France, 9Department of Radiotherapy, C.H.U. Brest - Hoˆpital Morvan, Brest, France, 10Department of Pulmonary Diseases, CH Rene Pleven, Dinan, France
Conclusions: ORR and PFS were significantly better in the ILD patients than in the irAEs-non-ILD and non-irAEs patients. Pre-existing history of IP was an independent risk factor of ILD-induced ICIs. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Annals of Oncology 1502P
First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Background: Pembrolizumab significantly improves progression-free survival (PFS) (median 10.3 months) and overall survival (OS) (median 30.0 months) in selected patients with previously untreated advanced non–small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) 50% and without EGFR/ALK aberrations. Data in real life conditions are missing. Methods: This was a cross-sectional, retrospective study of untreated advanced NSCLC patients with TPS 50% and without EGFR/ALK aberrations, from 9 French hospitals in Brittany area. The study included 115 patients and analysis focused on 108 patients. At index, the main characteristics of our cohort were: median age [range] 66.7 [37 to 87] years, 71 % male, 23.1 % performans status (P.S) 2, 88.8 % current or former smokers. 87.1 % had Stage IV at diagnosis and 9.2 % had untreated brain metastasis. 23.4% had mutations (KRAS, MET, BRAF and ROS 1). We used Kaplan-Meier analysis for PFS and described tolerability. Results: With a median follow-up of 7.1 months, median PFS was 10.1 months (95% confidence interval [CI], 8.8 to 11.4), (range, and 0.6 to 18.5 months). The objective response rate was 58,2% (complete response: 2.7 % and partial response: 55.5 %). Disease control rate was 72.1%. The estimated rate of OS at 6 months was 86.6 %. Treatment-related adverse events of grade 3 (AE) occurred in 7.4% of patients. There was no grade 4 or 5 AE and mean time between first administration of pembrolizumab and clinico-biological AE was 13.9 (6 9.7) weeks. Our data are immature to appreciate OS. Conclusions: In a real life cohort of patients (PS 2, untreated brain metastasis), with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab demonstrates similar PFS with KEYNOTE-024 phase III trial. Legal entity responsible for the study: Renaud Descourt. Funding: Association Bretonne de Cance´rologie Thoracique (ABCT). Disclosure: R. Corre: Travel / Accommodation / Expenses, Officer / Board of Directors: bms. G. Robinet: Advisory / Consultancy: MSD; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): BMS; Research grant / Funding (institution): Roche. R. Descourt: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: takeda; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Travel / Accommodation / Expenses: Pfizer. All other authors have declared no conflicts of interest. Linguistic correction
1503P
Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients
T. Sugano, M. Seike, Y. Saito, N. Takano, K. Hisakane, S. Takahashi, T. Tanaka, T. Kashiwada, S. Nakamichi, S. Takeuchi, A. Miyanaga, Y. Minegishi, R. Noro, K. Kubota, A. Gemma Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan Background: Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD associates with treatment efficacy and to research the characteristics of ILD in advanced non-small-cell lung cancer (NSCLC). Methods: Between December 2015 and November 2018, 132 advanced NSCLC patients were treated with nivolumab, pembrolizumab or atezolizumab. The patients were categorized into two groups (irAEs group or non-irAEs group). Subsequently, we extracted patients based on the incidence of ILD (ILD group). Treatment efficacy and characteristics of ILD were evaluated in each group. Results: The 39 (30%) patients developed irAEs. ILD was observed in 16 (12%) patients. Patients with ILD had significantly higher objective response rate (ORR) compared with irAEs-non-ILD patients and non-irAEs patients (63%, 43% and 22%, respectively). Median progression-free survival (mPFS) was 15.9 months in the ILD patients, 5.4 months in the irAEs-non-ILD patients and 3.3 months in the non-irAEs patients (Log rank, P ¼ 0.035). Pre-existing interstitial pneumonia (IP) was an independent risk factor of ILD-induced ICIs (odds ratios 15.1; 95% CI: 2.23-102, P ¼ 0.005).
Volume 30 | Supplement 5 | October 2019
1504P
Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Y. Kawashima1, O. Yamaguchi2, T. Kozuki3, N. Furuya4, F. Kurimoto5, T. Okuno6, T. Yamada7, K. Komiyama8, R. Ko9, Y. Nagai10, N. Ishikawa11, T. Harada12, K. Watanabe13, M. Seike14, K. Yoshimura15, K. Kobayashi2, H. Kagamu2 1 Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan, 2 Department of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama, Japan, 3Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, 4Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 5Thoracic Oncology, Saitama Cancer Center, Saitama, Japan, 6Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan, 7Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan, 8Department of Respiratory Medicine, Saitama Medical University Hospital, Saitama, Japan, 9Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan, 10Department of Pulmonary Medicine, Jichi Medical University, Tochigi, Japan, 11Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan, 12Center for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan, 13Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan, 14Division of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, 15 Department of Biostatistics, Innovative Clinical Research Center, Kanazawa University Hospital, Kanazawa, Japan Background: Although anti-PD-1 antibodies are the most promising agents in advanced non-small cell lung cancer (NSCLC), no definitive biomarkers of efficacy exist. We developed a novel assay for peripheral blood mononuclear cell (PBMC) biomarker using the prediction formula consisting of CD62L-downregulated (CD62Llow) CD4þT cells and CD25þFoxp3þCD4þT cells. This study aimed to validate it. Methods: This prospective multicenter phase II study included patients with treated advanced or metastatic NSCLC. After registration and PBMC biomarker analysis, they were classified into responder (RT) or non-responder (NRT) type. Nivolumab was administered every two weeks. The primary endpoint was disease control rate (DCR) at nine weeks after nivolumab treatment in RT patients. Desired and threshold DCR were set at 80% and 60%, respectively. Secondary endpoints were objective response rate (ORR), time to treatment failure, progression-free survival (PFS), overall survival, safety and tolerability, comparison with NRT patients, and PBMC biomarker quality improvement. Results: Of the 96 enrolled patients, 95 were eligible for PBMC analysis: 3 were unanalyzable, and 92 were analyzed; however, 40 had a minimal number of live cells. We excluded 19 patients who did not receive nivolumab in NRT and 1 with indeterminable treatment effect at nine weeks, and 72 patients comprised the per protocol set (PPS), of which 43 were RT and 29 NRT. The DCR and ORR in RT patients were 65.1% (95% confidence interval [CI], 50.9-79.4%) and 14.0% (95% CI, 3.6-24.3%), respectively. The PFS in RT patients was 113 days (95% CI, 65-158). As a subset analysis, we examined 45 patients (25 RT and 20 NRT) excluding those with 50% dead cell ratio in lymphocyte culture. The DCR was 80.0% (95%CI, 64.3-95.7) in RT and 50.0% (95% CI, 28.1-71.9) in NRT (chi-square test, p ¼ 0.034). Conclusions: In alive PBMC analysis, DCR was better in the RT than in the NRT patients. This PBMC biomarker using the ratio of CD62LlowCD4þT cells to CD25þFoxp3þCD4þT cells might be promising for predicting nivolumab efficacy. Clinical trial identification: UMIN ID: UMIN000028468. Legal entity responsible for the study: North East Japan Study Group (NEJSG). Funding: Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K. Disclosure: O. Yamaguchi: Research grant / Funding (institution): Nihon Medi-Physics Co., Ltd.; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Ono Pharmaceutical; Speaker Bureau / Expert testimony: Bristol-Myers Squibb. T. Kozuki: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Nippon Beohringer Ingelheim Co.; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical Co.; Honoraria (self): Kyowa-Hakko Kirin; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan; Research grant / Funding (institution): Merck Biopharm; Honoraria (self): MSD; Honoraria (self): Ono Pharmaceutical Co.; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical Co. N. Furuya: Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Lilly; Honoraria (self): Chugai Pharma ; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Ono Pharmaceutical. T. Yamada: Research grant / Funding (self): Ono Pharmaceutical Co., Ltd.; Research grant / Funding (self): Boehringer Ingelheim Japan Inc.; Research grant / Funding (self): Takeda Pharmaceutical Co. Ltd.; Research grant / Funding (self): Chugai Pharmaceutical Co., Ltd. R. Ko: Honoraria (self): Ono Pharmaceutical Co., Ltd. T. Harada: Honoraria (institution): Boehringer Ingelheim; Honoraria (institution): Hisamitsu Pharmaceutical Co., Inc; Honoraria (institution): GlaxoSmithKleine K.K. M. Seike: Honoraria (self), Research grant /
doi:10.1093/annonc/mdz260 | v617
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz260.025/5577677 by guest on 26 October 2019
K. Amrane1, M. Geier1, R. Corre2, G. Le´veiller3, G. Florence4, R. Lamy5, J.L. Bizec6, E. Goarant7, G. Robinet8, S. Ulrike9, G. Quere1, C. Bernier10, R. Descourt1 1 Department of Oncology, C.H.U. Brest - Hoˆpital Morvan, Brest, France, 2Department of Pulmonary Diseases, CHU de Pontchaillou, Rennes, France, 3Department of Pulmonary Diseases, CH Yves le Foll, Saint Brieuc, France, 4Department of Pulmonary Diseases, CH Pays de Morlaix, Morlaix, France, 5Department of Oncology, CH Bretagne Sud, Lorient, France, 6Department of Pulmonary Diseases, CH Bretagne-Atlantique, Vannes, France, 7 Department of Pulmonary Diseases, Hospital of Saint-Malo, Saint Malo, France, 8 Department of Oncology, C.H.U. Brest - Hoˆpital Morvan, Brest, France, 9Department of Radiotherapy, C.H.U. Brest - Hoˆpital Morvan, Brest, France, 10Department of Pulmonary Diseases, CH Rene Pleven, Dinan, France
Conclusions: ORR and PFS were significantly better in the ILD patients than in the irAEs-non-ILD and non-irAEs patients. Pre-existing history of IP was an independent risk factor of ILD-induced ICIs. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.